It is a reflection of the very significant potential of Evgen Pharma’s technology that the company has been able to attract a high calibre commercial, scientific and advisory team.
Directors and Senior Management
Barry Clare, Non-executive Chairman
Barry has over 20 years’ experience in the healthcare industry. He was a former main board director of the Boots Company plc and Chairman of University Hospital South Manchester (UHSM) Foundation Trust. As the former Managing Director of Boots Healthcare International, he led the global expansion of a leading portfolio of brands including Nurofen, Strepsils and Clearasil. Since leaving Boots, he has set up his own company, Clarat Partners LLP, and engineered several private equity backed transactions.
Dr Huw Jones, CEO
Dr Jones has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on pre-clinical and clinical drug development, dilutive and non-dilutive financing and business development. He is Chairman of Chronos Therapeutics Ltd, Non-Executive Director of IxaKa Ltd (formerly Rexgenero) and Strategic Advisor to Gen2 Neuroscience Ltd. Dr Jones holds a PhD in pharmacology from the University of Birmingham, UK.
Richard Moulson, Chief Financial Officer
Richard is a qualified chartered accountant with over 25 years’ post-qualification experience working as a chief financial officer for UK quoted and private equity and venture capital owned companies. Richard trained with Coopers & Lybrand and spent 10 years with Deutsche Morgan Grenfell in corporate finance working on fundraisings, IPOs and M&A transactions in the UK and internationally. He has considerable life science experience in companies including Intercytex Group Plc, ReNeuron Group plc and Cobra Therapeutics.
Dr Alan Barge, Non-Executive Director
Alan is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to proof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.
Dr Susan Foden, Non-Executive Director
Susan has broad experience in executive and non-executive roles at both public and private companies and at funding organisations. She has previously held the roles of: Senior Independent Director and Chair of the Remuneration Committee at Vectura plc, NED of BTG plc (through to their acquisition by Boston Scientific) and is a former Chair of BerGenBio AS. She is currently a director of QBiotics Ltd and is a member of the Investment Committee for CD3 – the joint drug discovery initiative between the University of Leuven and the European Investment Fund (EIF). She studied biochemistry at the University of Oxford, obtaining an MA and a DPhil.
Susan Clement-Davies, Non-Executive Director
Susan is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and most recently as Managing Director at Torreya Partners LLC, a global investment banking firm serving companies in the Life Sciences industry. Susan is currently Non-Executive Director and Chairman of the Audit Committee of Scancell Holdings PLC, Advisor to Theolytics and Member of the CW+ NHS Hospital Innovation Advisory Board. Susan has a BSc in Economics from University College London and a MSc in Economics from London School of Economics.
Dr Helen Kuhlman, Chief Business Officer
Dr Kuhlman has over 20 years’ experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies. She was previously at the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank’s portfolio companies. Prior to that Helen was Vice-President of Corporate Development at Chronos Therapeutics Ltd and was previously at Innovate UK where she created and delivered the £180m Biomedical Catalyst competitive grant scheme funded by the UK government. Dr Kuhlman holds a PhD in physiology and pharmacology from the University of Leicester, UK.